Ann: Neuren receives response to request for Breakthrough Therapy, page-54

Nice overreaction but not surprising in this space.
Ok BT rejection was disappointing, but that doesn't stop their pipeline progression.
I'm excited as we get close to the the next set of results.
What I luv about NEU is the multiple shots at goal and already a successful ph2 in Rhetts and remember this was only a short trial.
As a punt on a biotech goes, NEU ticks all the boxes, and at these levels I believe is a good buying opportunity.
BTW, I've been in NEU for a while, I bought at 2.3 cents originally, and more recently 10 cents and around 12 cents after the ph2 Rhetts results. I sold some at 17.5 cents to lock in some profits, but have retained my core parcel.